UK's No-Deal Brexit Plans Revealed For Medtech Sector
Executive Summary
The UK government has published a number of “technical notices” explaining what would change in the area of medical devices and pharmaceuticals in the event of a no-deal Brexit, and what stakeholders would need to do to prepare for such an eventuality.
You may also be interested in...
Brexit + MDR Equals Little Certainty For UK And EU Medtech Groups
Medtech stakeholders were reminded recently at the UK's largest regulatory forum that even those willing to make the best of Brexit are still working in the dark. The lack of useful government outreach is frustrating most efforts to secure business continuity. And that is without factoring in the huge regulatory changes that the EU's twin medical device regulations – the MDR and IVDR – will bring.
Pressing Timetable For UK Facing No-Deal Brexit Risk, More Technical Notices And Committee Work
The path of Brexit is not running smoothly for the UK in its negotiations with the EU on a withdrawal agreement featuring a free trade deal. Opportunities for these negotiations are running out. At home, the UK government has issued more "no deal" technical notices, and continues to run a busy parliamentary Brexit committee schedule.
Questions Abound: UK MHRA Brexit Proposal For Medtech Leaves Much Unsaid, Much To Fear
Questions outnumber answers for medtech following the UK's recently issued "technical notices" on the implications if the UK does not reach a Brexit agreement with the EU before March 2019. Below we list the critical outstanding questions based on a Medtech Insight analysis and discussion with several top experts in the field. These questions have also been put directly to the UK's MHRA and the European Commission.